Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Jean-Louis Montastruc19
Levodopa (adverse effects)41
Jean-Louis Montastruc Sauf Levodopa (adverse effects)" 14
Levodopa (adverse effects) Sauf Jean-Louis Montastruc" 36
Jean-Louis Montastruc Et Levodopa (adverse effects) 5
Jean-Louis Montastruc Ou Levodopa (adverse effects) 55
Corpus679
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 5.
Ident.Authors (with country if any)Title
000208 Jean-Louis Montastruc [France] ; Anne Charlotte Danton [France] ; Genevieve Durrieu [France] ; Isabelle Lacroix [France] ; Pascale Olivier [France] ; Agnés Sommet [France] ; Jean-Michel Senard [France]Neuropathy as a potential complication of levodopa use in Parkinson's disease: A Pharmacological and Pharmacovigilance point of view
000223 Santiago Perez-Lloret [France] ; Emmanuelle Bondon-Guitton [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Adverse drug reactions to dopamine agonists: A comparative study in the french pharmacovigilance database
000518 Jean-Louis Montastruc [France]Treatment of Parkinson's disease should begin with a dopamine agonist
000616 Jean-Louis Montastruc [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; André Rascol [France]Does fluoxetine aggravate Parkinson's disease? A pilot prospective study
000629 Rascol [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Janet Poulik [France] ; Umberto Sabatini [France] ; Jean-Michel Senard [France] ; Michèle Ané [France] ; Jean-Louis Montastruc [France] ; André Rascol [France]Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024